0001567619-21-011941.txt : 20210609
0001567619-21-011941.hdr.sgml : 20210609
20210609181254
ACCESSION NUMBER: 0001567619-21-011941
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210607
FILED AS OF DATE: 20210609
DATE AS OF CHANGE: 20210609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dillon Michael P.
CENTRAL INDEX KEY: 0001777415
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 211006268
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
doc1.xml
FORM 4
X0306
4
2021-06-07
0
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001777415
Dillon Michael P.
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
SVP, Chief Scientific Officer
Common Stock
2021-06-07
4
M
0
1500
6.92
A
100289
D
Common Stock
2021-06-07
4
S
0
1500
20.2221
D
98789
D
Stock Option (right to buy)
6.92
2021-06-07
4
M
0
1500
0.00
D
2030-02-20
Common Stock
1500
51000
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $19.95 to $20.495, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
2021-06-08